PCN77 Cost Effectiveness Analysis in the Veneto Region of Nab-Paclitaxel Monotherapy II Line Versus Conventional Paclitaxel in Patients With Breast Cancer and for Whom Anthracyclines are Not Indicated
Nov 1, 2012, 00:00 AM
10.1016/j.jval.2012.08.2117
https://www.valueinhealthjournal.com/article/S1098-3015(12)03831-4/fulltext
Section Title :
Cancer
Section Order :
770
First Page :
A423
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(12)03831-4&doi=10.1016/j.jval.2012.08.2117